Is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for specific cancers.

About us

CellCentric is a UK based biotechnology company with offices in Cambridge, Oxford and Manchester (Alderley Park). It has partnered and collaborated with researchers and clinicians across the world, from West Coast USA to Japan. The company is privately held; it’s lead investor is Boston based, Morningside Ventures.

The company’s leadership has deep R&D experience gained in academia, large pharma and biotechs, spanning from basic biological research through to international clinical development programmes.

Our history

CellCentric was originally formed out of the University of Cambridge, drawing on the work of one of the pioneers of epigenetics, Prof Azim Surani FRS CBE.

Over time the company has investigated a wide range of epigenetic-related pathways to address disease. More than 50 potential drug targets have been investigated, before focussing on p300/CBP. The selection was driven by strong biological understanding, a clear path for developing selective and potent small molecule inhibitor drugs, as well as well-defined relevance and targeted application to treat cancer.

An early arginine methyltransferase programme was licenced to Takeda Pharmaceuticals.

CCS1477 and its application

CellCentric’s first-in-class drug is a small molecule that inhibits the conserved bromodomain of p300 and CBP. It was developed by the company from initial hits through to an optimised compound and clinical candidate. It is formulated as a capsule taken orally.

The compound has been evaluated extensively pre-clinically, demonstrating its impact on p300/CBP inhibition in vivo. P300/CBP affects the expression of the androgen receptor (AR), as well as its variants. It also impacts MYC and IRF4. This mechanism of action links through to the treatment of specific cancer types; late stage, drug resistant, prostate cancer and haematological malignancies (including multiple myeloma and acute myeloid leukaemia).

Certain tumours over-express AR and MYC. Other tumours have loss of function mutations in either p300 or CBP. These molecularly driven cancer types can be specifically targeted with CCS1477. These tumours can be wide ranging, and include lymphomas, lung, bladder and breast cancers.

Clinical trials

CCS1477 is currently being evaluated in Phase I/II clinical trials in multiple clinical centres in the UK. The prostate cancer programme is led by Prof Johann de Bono at the Royal Marsden Hospital/Institute of Cancer Research, London. The haematological malignancy programme is led by Prof Tim Somervaille, the Christie Hospital, Manchester.

Potential suitability for enrolment in a CCS1477 clinical trial will be made by oncologists at our participating hospitals, and not by CellCentric. Any advice on clinical study options should come from your general practitioner and/or oncologist.